American Shared Hospital Services (AMS) 10-Q 7 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Nov. 01, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Entity Registrant Name	American Shared Hospital Services
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		5,816
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000744825
Current Fiscal Year End Date	--12-31
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 1,297	$ 1,442
Restricted cash	350	350
Accounts receivable, net of allowance for doubtful accounts of $100,000 at September 30, 2019 and $100,000 at December 31, 2018	6,511	5,502
Other receivables insurance proceeds	0	1,137
Other receivables	261	239
Prepaid expenses and other current assets	1,825	1,276
Total current assets	10,244	9,946
Property and equipment:
Medical equipment and facilities	90,672	94,031
Office equipment	578	589
Deposits and construction in progress	5,589	6,082
Property and equipment, gross	96,839	100,702
Accumulated depreciation and amortization	(53,836)	(54,008)
Net property and equipment	43,003	46,694
Right of use assets	1,173	0
Other assets	838	862
Total assets	55,258	57,502
Current liabilities:
Accounts payable	1,097	435
Employee compensation and benefits	289	207
Other accrued liabilities	1,482	1,329
Other accrued liabilities insurance payable	0	977
Current portion of lease liabilities	272	0
Current portion of long-term debt	1,666	2,119
Current portion of obligations under capital leases	3,972	4,407
Total current liabilities	8,778	9,474
Long-term lease liabilities, less current portion	901	0
Long-term debt, less current portion	2,230	3,332
Long-term capital leases, less current portion	8,881	10,308
Deferred revenue, less current portion	302	382
Deferred income taxes	2,744	2,958
Shareholders' equity:
Common stock, no par value (10,000,000 authorized; 5,816,000 and 5,714,000 shares issued and outstanding at September 30, 2019 and at December 31, 2018)	10,752	10,711
Additional paid-in capital	6,665	6,495
Retained earnings	8,362	7,896
Total equity-American Shared Hospital Services	25,779	25,102
Non-controlling interest in subsidiary	5,643	5,946
Total shareholders' equity	31,422	31,048
Total liabilities and shareholders' equity	$ 55,258	$ 57,502

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) [Parenthetical] - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Allowance for doubtful accounts (in dollars)	$ 100	$ 100
Common stock, shares authorized (in shares)	10,000,000	10,000,000
Common Stock
Common stock, shares issued (in shares)	5,816,000	5,714,000
Common stock, shares outstanding (in shares)	5,816,000	5,714,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues	$ 5,301	$ 4,470	$ 15,819	$ 14,944
Costs of revenue:
Maintenance and supplies	648	470	1,968	1,723
Depreciation and amortization	1,817	1,761	5,719	5,082
Other direct operating costs	1,023	605	2,653	2,218
Costs of revenue	3,488	2,836	10,340	9,023
Gross Margin	1,813	1,634	5,479	5,921
Selling and administrative expense	1,065	1,050	3,201	3,067
Interest expense	302	399	1,015	1,230
Operating income	446	185	1,263	1,624
Proceeds received from investment in equity securities	0	0	0	22
Interest and other income	7	185	15	194
Income before income taxes	453	370	1,278	1,840
Income tax expense	99	82	250	401
Net income	354	288	1,028	1,439
Less: Net income attributable to non-controlling interest	(189)	(120)	(562)	(594)
Net income attributable to American Shared Hospital Services	$ 165	$ 168	$ 466	$ 845
Net income per share:
Earnings per common share - basic (in USD per share)	$ 0.03	$ 0.03	$ 0.08	$ 0.14
Earnings per common share - diluted (in USD per share)	$ 0.03	$ 0.03	$ 0.08	$ 0.14

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Sub-Total ASHS	Non-controlling Interests in Subsidiaries
Beginning balance at Dec. 31, 2017	$ 29,885	$ 10,711	$ 6,272	$ 6,873	$ 23,856	$ 6,029
Beginning balance (in shares) at Dec. 31, 2017		5,710
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	55	$ 0	55	0	55	0
Stock-based compensation expense (in shares)		0
Net income	651	$ 0	0	390	390	261
Ending balance at Mar. 31, 2018	30,591	$ 10,711	6,327	7,263	24,301	6,290
Ending balance (in shares) at Mar. 31, 2018		5,710
Beginning balance at Dec. 31, 2017	29,885	$ 10,711	6,272	6,873	23,856	6,029
Beginning balance (in shares) at Dec. 31, 2017		5,710
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,439
Ending balance at Sep. 30, 2018	31,023	$ 10,711	6,441	7,718	24,870	6,153
Ending balance (in shares) at Sep. 30, 2018		5,714
Beginning balance at Mar. 31, 2018	30,591	$ 10,711	6,327	7,263	24,301	6,290
Beginning balance (in shares) at Mar. 31, 2018		5,710
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	57	$ 0	57	0	57	0
Stock-based compensation expense (in shares)		4
Cash distributions to non-controlling interests	(77)	$ 0	0	0	0	(77)
Net income	500	0	0	287	287	213
Ending balance at Jun. 30, 2018	31,071	$ 10,711	6,384	7,550	24,645	6,426
Ending balance (in shares) at Jun. 30, 2018		5,714
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	57	$ 0	57	0	57	0
Stock-based compensation expense (in shares)		0
Cash distributions to non-controlling interests	(393)	$ 0	0	0	0	(393)
Net income	288	0	0	168	168	120
Ending balance at Sep. 30, 2018	31,023	$ 10,711	6,441	7,718	24,870	6,153
Ending balance (in shares) at Sep. 30, 2018		5,714
Beginning balance at Dec. 31, 2018	31,048	$ 10,711	6,495	7,896	25,102	5,946
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	55	$ 0	55	0	55	0
Stock-based compensation expense (in shares)		0
Cash distributions to non-controlling interests	(19)	$ 0	0	0	0	(19)
Net income	395	0	0	270	270	125
Ending balance at Mar. 31, 2019	31,479	$ 10,711	6,550	8,166	25,427	6,052
Ending balance (in shares) at Mar. 31, 2019		5,714
Beginning balance at Dec. 31, 2018	31,048	$ 10,711	6,495	7,896	25,102	5,946
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 1,028
Options exercised (in shares)	16
Ending balance at Sep. 30, 2019	$ 31,422	10,752	6,665	8,362	25,779	5,643
Beginning balance at Mar. 31, 2019	31,479	10,711	6,550	8,166	25,427	6,052
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	53	$ 0	53	0	53	0
Stock-based compensation expense (in shares)		86
Cash distributions to non-controlling interests	(57)	$ 0	0	0	0	(57)
Net income	279	0	0	31	31	248
Ending balance at Jun. 30, 2019	31,754	$ 10,711	6,603	8,197	25,511	6,243
Ending balance (in shares) at Jun. 30, 2019		5,800
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	62	$ 0	62	0	62	0
Stock-based compensation expense (in shares)		0
Cash distributions to non-controlling interests	(789)	$ 0	0	0	0	(789)
Net income	354	0	0	165	165	189
Options exercised	41	$ 41	0	0	41	0
Options exercised (in shares)		16
Ending balance at Sep. 30, 2019	$ 31,422	$ 10,752	$ 6,665	$ 8,362	$ 25,779	$ 5,643

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities:
Net income	$ 1,028	$ 1,439
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	5,772	5,138
Non cash lease expense	189	0
Deferred income tax	(214)	45
Stock-based compensation expense	170	169
Net accrued interest on lease financing	9	39
Interest expense associated with lease liabilities	59	0
Changes in operating assets and liabilities:
Receivables	(896)	(398)
Prepaid expenses and other assets	(559)	(473)
Customer deposits/deferred revenue	(60)	(93)
Lease liability	(248)	0
Accounts payable and accrued liabilities	877	359
Net cash provided by operating activities	6,127	6,225
Investing activities:
Payment for purchase of property and equipment	(889)	(1,187)
Proceeds from insurance	160	0
Net cash used in investing activities	(729)	(1,187)
Financing activities:
Principal payments on long-term debt	(1,564)	(1,875)
Principal payments on capital leases	(3,155)	(3,006)
Distributions to non-controlling interests	(865)	(470)
Proceeds from options exercised	41	0
Net cash used in financing activities	(5,543)	(5,351)
Net change in cash, cash equivalents, and restricted cash	(145)	(313)
Cash, cash equivalents, and restricted cash at beginning of period	1,792	2,502
Cash, cash equivalents, and restricted cash at end of period	1,647	2,189
Supplemental cash flow disclosure:
Interest Paid, Excluding Capitalized Interest, Operating Activities	1,015	1,307
Income taxes paid	418	277
Schedule of non-cash investing and financing activities
Right of use assets and lease liabilities	1,362	0
Interest capitalized to property and equipment	82	77
Acquisition of equipment with capital lease financing	$ 1,293	$ 1,679

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company generally calculates its effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, the Company computes its provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. The Company’s effective income tax rate is highly influenced by relative income or losses reported and the amount of the nondeductible stock-based compensation associated with grants of its common stock options and from the results of foreign operations. A small change in estimated annual pretax income (loss) can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, the Company has computed its provision for income taxes for the three and nine-month periods ended September 30, 2019 by applying the actual effective tax rates to income or (loss) reported within the condensed consolidated financial statements through those periods.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for the fair presentation of American Shared Hospital Services’ consolidated financial position as of September 30, 2019, the results of its operations for the three and nine-month periods ended September 30, 2019 and 2018, and the cash flows for the three and nine-month periods ended September 30, 2019 and 2018. The results of operations for the three and nine-months ended September 30, 2019 are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2018 have been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2018 included in American Shared Hospital Services’ Annual Report on Form 10-K filed with the Securities and Exchange Commission. These consolidated financial statements include the accounts of American Shared Hospital Services and its subsidiaries (the “Company”) as follows: the Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), OR21, Inc., and MedLeader.com, Inc. (“MedLeader”); the Company is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”); GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. As of September 30, 2019, GKF provides Gamma Knife units to fifteen medical centers in the United States in the states of Arkansas, California, Florida, Illinois, Indiana, Massachusetts, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, Tennessee, and Texas. GKF also owns and operates a single-unit Gamma Knife facility in Lima, Peru. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy, Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts. The Company formed the subsidiaries GKPeru for the purposes of expanding its business internationally; Orlando and LBE to provide proton beam therapy equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for The Operating Room for the 21st Century SM through its 50% owned OR21, LLC (“OR21 LLC”). The remaining 50% is owned by an architectural design company. OR21 LLC is not expected to generate significant revenue for at least the next two years. MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time. All significant intercompany accounts and transactions have been eliminated in consolidation. Accounting Pronouncements Issued and Adopted Based on the guidance provided in accordance with Accounting Standards Codification (“ASC”) 280 Segment Reporting (“ASC 280”), the Company has analyzed its subsidiaries which are all in the business of leasing radiosurgery and radiation therapy equipment to healthcare providers, and concluded there is one reportable segment, Revenues. The Company provides Gamma Knife, PBRT, and IGRT equipment to sixteen hospitals in the United States and owns and operates a single-unit facility in Lima, Peru as of September 30, 2019. These seventeen locations operate under different subsidiaries of the Company but offer the same services: radiosurgery and radiation therapy. The operating results of the subsidiaries are reviewed by the Company’s Chief Executive Officer and Chief Financial Officer, who are also deemed the Company’s Chief Operating Decision Makers (“CODMs”) and this is done in conjunction with all of the subsidiaries and locations. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02 Leases (“ASU 2016-02”) which requires lessees to recognize, for all leases, at the commencement date, a lease liability, and a right-of-use asset. Under the new guidance, lessor classification criteria for direct financing and sales-type leases is modified. In July 2018, the FASB issued ASU No. 2018-10 Leases (Topic 842) Codification Improvements to Topic 842 , and ASU No. 2018-11 Leases (Topic 842) Targeted Improvements (“ASU 2018-11”), in December 2018 the FASB issued ASU No. 2018-20 Leases (Topic 842) Narrow-Scope Improvements , and in February 2019 the FASB issued ASU No. 2019-01 Leases (Topic 842) Codification Improvements . ASU 2018-11 provides a new transition method in which an entity can initially apply the new lease standards at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This standard is effective for annual periods beginning after December 15, 2018. The Company performed an analysis to determine if its revenue agreements with customers fall under the scope of ASU 2016-02 or ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and concluded that, other than with respect to the Company’s stand-alone facility in Lima, Peru, ASU 2016-02 applied. The Company adopted ASU 2016-02 and related ASUs as of January 1, 2019 using the modified retrospective transition method. The Company elected to initially apply ASU 2016-02 and related ASUs beginning January 1, 2019 and elected to use the package of practical expedients upon adoption. The provisions of the package of practical expedients allowed the Company to not reassess whether any expired or existing contracts are or contain leases, the lease classification for expired or existing contracts, and the Company need not reassess the initial direct costs for any existing leases. The Company also used the hindsight expedient upon adoption which allowed the Company to examine its history when assessing lease term and whether it will exercise renewal options for certain contracts. The Company recognized lease liabilities and right-of-use assets of approximately $1,362,000 for its operating leases at January 1, 2019, with no initial material impact to its consolidated statements of operations. In July 2019, the FASB issued ASU 2019-07 Codification Updates to SEC Sections: Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization, and Miscellaneous Updates ("ASU 2019-07") which clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning with the SEC's regulations, thereby eliminating redundancies and making the codification easier to apply. The new guidance was effective immediately upon issuance and did not have a material impact on the Company's financial statements and related disclosures. Accounting Pronouncements Issued and Not Yet Adopted In February 2018, the FASB issued ASU No. 2018-03 Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2018-03”), which clarifies certain aspects of ASU 2016-01. These are: equity securities without a readily determinable fair value – discontinuation, equity securities without a readily determinable fair value – adjustments, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements to Fair Value Measurement (“ASU 2018-13”), which amended the effective date and other certain measurement aspects of ASU 2018-03. The new guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company does not expect ASU 2018-03 or ASU 2018-13 to have a significant impact on its consolidated financial statements and related disclosures.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife, IGRT, and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where indicated. Salvage value is based on the estimated fair value of the equipment at the end of its useful life. Depreciation for PBRT equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years. The following table summarizes property and equipment as of September 30, 2019 and December 31, 2018: September 30, December 31, 2019 2018 Medical equipment and facilities $ 90,672,000 $ 94,031,000 Office equipment 578,000 589,000 Deposits and construction in progress 3,339,000 3,832,000 Deposits towards purchase of proton beam systems 2,250,000 2,250,000 96,839,000 100,702,000 Accumulated depreciation (53,836,000) (54,008,000) Net property and equipment $ 43,003,000 $ 46,694,000 As of September 30, 2019, approximately $2,961,000 of the net property and equipment balance is outside of the United States. As of September 30, 2019, the Company has one idle Gamma Knife unit with a cumulative net book value of $729,000. There are currently no commitments to place into service or trade in this unit during 2019.

Long-Term Debt Financing

Long-Term Debt Financing	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Long-term Debt Financing	Long-Term Debt FinancingLong-term debt consists of seven notes with three financing companies collateralized by the Gamma Knife equipment, the individual customer contracts, and related accounts receivable at September 30, 2019. As of September 30, 2019, long-term debt on the Condensed Consolidated Balance Sheets was $3,896,000. See disclosure of future payments below under the heading “Commitments”.

Capital Lease Financing

Capital Lease Financing	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Capital Lease Financing	Capital Lease FinancingCapital lease financing consists of ten leases with three financing companies, collateralized by Gamma Knife and PBRT equipment, the individual customer contracts, and related accounts receivable at September 30, 2019. As of September 30, 2019, obligations under capital leases on the Condensed Consolidated Balance Sheets were $12,853,000. See disclosure of future payments below under the heading “Commitments”.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Leases The Company determines if a contract is a lease at inception. Under ASC 842 Leases (“ASC 842”), the Company is a lessor of equipment to various customers. Leases that commenced prior to ASC 842 adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. All of the Company’s lessor arrangements entered into after ASC 842 adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do not contain the option to terminate early or purchase the asset at the end of the term. The Company’s Gamma Knife, PBRT, and IGRT contracts with hospitals are classified as operating leases under ASC 842. The related equipment is included in medical equipment and facilities on the Company’s condensed consolidated balance sheets (see further discussion at Note 2). As all income from the Company’s lessor arrangements is solely based on procedure volume, all income is considered variable payments not dependent on an index or a rate. As such, the Company does not measure future operating lease receivable. The Company’s lessee operating leases are accounted for as right-of-use (“ROU”) assets, other current liabilities, and lease liabilities on the condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s operating lease contracts do not provide an implicit rate for calculating the present value of future lease payments, so the Company determined its incremental borrowing rate of approximately 6.0% by using available market rates and expected lease terms. The operating lease ROU assets and liabilities also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.The Company’s lessee operating lease agreements are for administrative office space and related equipment, and the agreement to lease clinic space for its stand-alone facility in Lima, Peru. These leases have remaining lease terms between 3 and 5 years, some of which include options to renew or extend the lease. As of September 30, 2019, operating ROU assets and liabilities were $1,173,000. The following table summarizes maturities of lessee operating lease ROU assets and liabilities as of September 30, 2019: Year ending December 31, Operating Leases 2019 (excluding the nine-months ended September 30, 2019) $ 84,000 2020 340,000 2021 347,000 2022 331,000 2023 214,000 Thereafter 6,000 Total lease payments 1,322,000 Less imputed interest (149,000) Total $ 1,173,000

Per Share Amounts

Per Share Amounts	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Per Share Amounts	Per Share Amounts Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The computation for the three and nine-month periods ended September 30, 2019 excluded approximately 513,000 of the Company’s stock options because the exercise price of the options was higher than the average market price during those periods. The computation for the three and nine-month periods ended September 30, 2018 excluded approximately 176,000 and 519,000, respectively, of the Company's stock options because the exercise price of the options was higher than the average market price during those periods. Based on the guidance provided in accordance with ASC 260 Earnings Per Share (“ASC 260”), the weighted average common shares for basic earnings per share, for the three and nine-month periods ended September 30, 2019 and 2018, excluded the weighted average impact of the unvested performance share awards, discussed below. These awards are legally outstanding but are not deemed participating securities and therefore are excluded from the calculation of basic earnings per share. The unvested shares are also excluded from the denominator for diluted earnings per share because they are considered contingent shares not deemed probable as of September 30, 2019. The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September 30, 2019 and 2018: Three Months ended September 30, Nine Months ended September 30, 2019 2018 2019 2018 Net income attributable to American Shared Hospital Services $ 165,000 $ 168,000 $ 466,000 $ 845,000 Weighted average common shares for basic earnings per share 5,889,000 5,841,000 5,899,000 5,831,000 Diluted effect of stock options and restricted stock 19,000 50,000 18,000 24,000 Weighted average common shares for diluted earnings per share 5,908,000 5,891,000 5,917,000 5,855,000 Basic earnings per share $ 0.03 $ 0.03 $ 0.08 $ 0.14 Diluted earnings per share $ 0.03 $ 0.03 $ 0.08 $ 0.14

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation In June 2010, the Company’s shareholders approved an amendment and restatement of the Company’s stock incentive plan, renaming it the Incentive Compensation Plan (the “Plan”), and among other things, increasing the number of shares of the Company’s common stock reserved for issuance under the Plan to 1,630,000. The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. The Plan is a successor to the Company’s previous plans, and any shares awarded and outstanding under those plans were transferred to the Plan. No further grants or share issuances will be made under the previous plans. On June 21, 2019, the Company’s shareholders approved an amendment and restatement of the Plan in order to extend the term of the Plan by two years to February 22, 2022. Stock-based compensation expense associated with the Company’s stock options to employees is calculated using the Black-Scholes valuation model. The Company’s stock awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award (requisite service period), usually the vesting period. Accordingly, stock-based compensation cost before income tax effect for the Company’s options and restricted stock units in the amount of $62,000 and $170,000 is reflected in net income for the three and nine-month periods ended September 30, 2019 compared to $57,000 and $169,000 in the same periods of the prior year, respectively. At September 30, 2019, there was approximately $94,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan, excluding unrecognized compensation cost associated with the performance share awards, discussed below. This cost is expected to be recognized over a period of approximately five years. On January 4, 2017, the Company entered into a Performance Share Award Agreement with three executive officers of the Company (the “Award Agreements”) for 161,766 restricted stock awards which vest upon the achievement of certain performance metrics. The Award Agreements expire on March 31, 2020. Based on the guidance in ASC 718 Stock Compensation (“ASC 718”), the Company concluded these were performance-based awards with vesting criteria tied to performance metrics. As of December 31, 2017, the Company achieved one of those certain performance metrics under the Award Agreements and recognized stock compensation expense of approximately $108,000 related to these awards. As of September 30, 2019, it is not probable that any of the remaining required metrics for vesting will be achieved. The unrecognized stock-based compensation expense for these awards was approximately $434,000 and unvested awards were approximately 129,000 shares as of September 30, 2019. If and when the Company determines that the remaining performance metrics’ achievement becomes probable, the Company will record a cumulative catch-up stock-based compensation amount and the remaining unrecognized amount will be recorded over the remaining requisite service period of the awards. The following table summarizes stock option activity for the nine-month periods ended September 30, 2019 and 2018: Stock Grant Date Weighted- Intrinsic Outstanding at January 1, 2019 613,000 $ 2.85 3.18 $ — Granted 18,000 $ 2.91 7.00 $ — Exercised (16,000) $ 2.59 — $ — Forfeited (12,000) $ 3.05 — $ — Outstanding at September 30, 2019 603,000 $ 2.86 2.09 $ 42,000 Exercisable at September 30, 2019 478,000 $ 2.86 1.97 $ — Outstanding at January 1, 2018 615,000 $ 2.87 3.48 $ — Granted 16,000 $ 2.68 6.96 $ — Forfeited (18,000) $ 3.15 — $ — Outstanding at September 30, 2018 613,000 $ 2.85 2.93 $ 337,000 Exercisable at September 30, 2018 389,000 $ 2.86 2.83 $ —

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for the fair presentation of American Shared Hospital Services’ consolidated financial position as of September 30, 2019, the results of its operations for the three and nine-month periods ended September 30, 2019 and 2018, and the cash flows for the three and nine-month periods ended September 30, 2019 and 2018. The results of operations for the three and nine-months ended September 30, 2019 are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2018 have been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2018 included in American Shared Hospital Services’ Annual Report on Form 10-K filed with the Securities and Exchange Commission. These consolidated financial statements include the accounts of American Shared Hospital Services and its subsidiaries (the “Company”) as follows: the Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), OR21, Inc., and MedLeader.com, Inc. (“MedLeader”); the Company is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”); GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. As of September 30, 2019, GKF provides Gamma Knife units to fifteen medical centers in the United States in the states of Arkansas, California, Florida, Illinois, Indiana, Massachusetts, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, Tennessee, and Texas. GKF also owns and operates a single-unit Gamma Knife facility in Lima, Peru. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy, Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts. The Company formed the subsidiaries GKPeru for the purposes of expanding its business internationally; Orlando and LBE to provide proton beam therapy equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for The Operating Room for the 21st Century SM through its 50% owned OR21, LLC (“OR21 LLC”). The remaining 50% is owned by an architectural design company. OR21 LLC is not expected to generate significant revenue for at least the next two years. MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time. All significant intercompany accounts and transactions have been eliminated in consolidation.
Accounting Pronouncements Issued	Accounting Pronouncements Issued and Adopted Based on the guidance provided in accordance with Accounting Standards Codification (“ASC”) 280 Segment Reporting (“ASC 280”), the Company has analyzed its subsidiaries which are all in the business of leasing radiosurgery and radiation therapy equipment to healthcare providers, and concluded there is one reportable segment, Revenues. The Company provides Gamma Knife, PBRT, and IGRT equipment to sixteen hospitals in the United States and owns and operates a single-unit facility in Lima, Peru as of September 30, 2019. These seventeen locations operate under different subsidiaries of the Company but offer the same services: radiosurgery and radiation therapy. The operating results of the subsidiaries are reviewed by the Company’s Chief Executive Officer and Chief Financial Officer, who are also deemed the Company’s Chief Operating Decision Makers (“CODMs”) and this is done in conjunction with all of the subsidiaries and locations. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02 Leases (“ASU 2016-02”) which requires lessees to recognize, for all leases, at the commencement date, a lease liability, and a right-of-use asset. Under the new guidance, lessor classification criteria for direct financing and sales-type leases is modified. In July 2018, the FASB issued ASU No. 2018-10 Leases (Topic 842) Codification Improvements to Topic 842 , and ASU No. 2018-11 Leases (Topic 842) Targeted Improvements (“ASU 2018-11”), in December 2018 the FASB issued ASU No. 2018-20 Leases (Topic 842) Narrow-Scope Improvements , and in February 2019 the FASB issued ASU No. 2019-01 Leases (Topic 842) Codification Improvements . ASU 2018-11 provides a new transition method in which an entity can initially apply the new lease standards at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This standard is effective for annual periods beginning after December 15, 2018. The Company performed an analysis to determine if its revenue agreements with customers fall under the scope of ASU 2016-02 or ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and concluded that, other than with respect to the Company’s stand-alone facility in Lima, Peru, ASU 2016-02 applied. The Company adopted ASU 2016-02 and related ASUs as of January 1, 2019 using the modified retrospective transition method. The Company elected to initially apply ASU 2016-02 and related ASUs beginning January 1, 2019 and elected to use the package of practical expedients upon adoption. The provisions of the package of practical expedients allowed the Company to not reassess whether any expired or existing contracts are or contain leases, the lease classification for expired or existing contracts, and the Company need not reassess the initial direct costs for any existing leases. The Company also used the hindsight expedient upon adoption which allowed the Company to examine its history when assessing lease term and whether it will exercise renewal options for certain contracts. The Company recognized lease liabilities and right-of-use assets of approximately $1,362,000 for its operating leases at January 1, 2019, with no initial material impact to its consolidated statements of operations. In July 2019, the FASB issued ASU 2019-07 Codification Updates to SEC Sections: Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization, and Miscellaneous Updates ("ASU 2019-07") which clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning with the SEC's regulations, thereby eliminating redundancies and making the codification easier to apply. The new guidance was effective immediately upon issuance and did not have a material impact on the Company's financial statements and related disclosures. Accounting Pronouncements Issued and Not Yet Adopted In February 2018, the FASB issued ASU No. 2018-03 Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2018-03”), which clarifies certain aspects of ASU 2016-01. These are: equity securities without a readily determinable fair value – discontinuation, equity securities without a readily determinable fair value – adjustments, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements to Fair Value Measurement (“ASU 2018-13”), which amended the effective date and other certain measurement aspects of ASU 2018-03. The new guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company does not expect ASU 2018-03 or ASU 2018-13 to have a significant impact on its consolidated financial statements and related disclosures.

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	The following table summarizes property and equipment as of September 30, 2019 and December 31, 2018: September 30, December 31, 2019 2018 Medical equipment and facilities $ 90,672,000 $ 94,031,000 Office equipment 578,000 589,000 Deposits and construction in progress 3,339,000 3,832,000 Deposits towards purchase of proton beam systems 2,250,000 2,250,000 96,839,000 100,702,000 Accumulated depreciation (53,836,000) (54,008,000) Net property and equipment $ 43,003,000 $ 46,694,000

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Summary of Maturities of Lessee Operating Lease	The following table summarizes maturities of lessee operating lease ROU assets and liabilities as of September 30, 2019: Year ending December 31, Operating Leases 2019 (excluding the nine-months ended September 30, 2019) $ 84,000 2020 340,000 2021 347,000 2022 331,000 2023 214,000 Thereafter 6,000 Total lease payments 1,322,000 Less imputed interest (149,000) Total $ 1,173,000

Per Share Amounts (Tables)

Per Share Amounts (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September 30, 2019 and 2018: Three Months ended September 30, Nine Months ended September 30, 2019 2018 2019 2018 Net income attributable to American Shared Hospital Services $ 165,000 $ 168,000 $ 466,000 $ 845,000 Weighted average common shares for basic earnings per share 5,889,000 5,841,000 5,899,000 5,831,000 Diluted effect of stock options and restricted stock 19,000 50,000 18,000 24,000 Weighted average common shares for diluted earnings per share 5,908,000 5,891,000 5,917,000 5,855,000 Basic earnings per share $ 0.03 $ 0.03 $ 0.08 $ 0.14 Diluted earnings per share $ 0.03 $ 0.03 $ 0.08 $ 0.14

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	The following table summarizes stock option activity for the nine-month periods ended September 30, 2019 and 2018: Stock Grant Date Weighted- Intrinsic Outstanding at January 1, 2019 613,000 $ 2.85 3.18 $ — Granted 18,000 $ 2.91 7.00 $ — Exercised (16,000) $ 2.59 — $ — Forfeited (12,000) $ 3.05 — $ — Outstanding at September 30, 2019 603,000 $ 2.86 2.09 $ 42,000 Exercisable at September 30, 2019 478,000 $ 2.86 1.97 $ — Outstanding at January 1, 2018 615,000 $ 2.87 3.48 $ — Granted 16,000 $ 2.68 6.96 $ — Forfeited (18,000) $ 3.15 — $ — Outstanding at September 30, 2018 613,000 $ 2.85 2.93 $ 337,000 Exercisable at September 30, 2018 389,000 $ 2.86 2.83 $ —

Basis of Presentation (Details

Basis of Presentation (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)segment	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Number of reportable segments | segment	1
Operating lease, liability	$ 1,173
Operating lease, right-of-use asset	$ 1,173		$ 0
Accounting Standards Update 2016-02
Operating lease, liability		$ 1,362
Operating lease, right-of-use asset		$ 1,362
OR21 LLC
Equity method investment, ownership percentage	50.00%
Architectural Design Company
Equity method investment, ownership percentage	50.00%

Property and Equipment (Details

Property and Equipment (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 43,003	$ 46,694
Outside of the United States
Property, Plant and Equipment [Line Items]
Property and equipment, net	2,961
Gamma Knife
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 729
Medical Equipment and Facilities | Minimum
Property, Plant and Equipment [Line Items]
Useful life	3 years
Medical Equipment and Facilities | Maximum
Property, Plant and Equipment [Line Items]
Useful life	10 years
PBRT Equipment
Property, Plant and Equipment [Line Items]
Useful life	20 years

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 96,839	$ 100,702
Accumulated depreciation	(53,836)	(54,008)
Net property and equipment	43,003	46,694
Medical equipment and facilities
Property, Plant and Equipment [Line Items]
Property and equipment, gross	90,672	94,031
Office equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	578	589
Deposits and construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,339	3,832
Deposits towards purchase of proton beam systems
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,250	$ 2,250

Long-Term Debt Financing (Detai

Long-Term Debt Financing (Details Textual) $ in Thousands	Sep. 30, 2019USD ($)note
Debt Disclosure [Abstract]
Number of debt instruments | note	7
Long-term debt | $	$ 3,896

Capital Lease Financing (Detail

Capital Lease Financing (Details Textual) $ in Thousands	Sep. 30, 2019USD ($)lease
Debt Disclosure [Abstract]
Number of financing leases | lease	10
Capital lease obligations | $	$ 12,853

Leases (Details Textual)

Leases (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Operating Leased Assets [Line Items]
Lessee, operating lease, discount rate	6.00%
Operating lease, right-of-use asset	$ 1,173	$ 0
Operating lease, liability	$ 1,173
Minimum
Operating Leased Assets [Line Items]
Operating lease remaining lease term (in years)	3 years
Maximum
Operating Leased Assets [Line Items]
Operating lease remaining lease term (in years)	5 years

Leases - Summary of Maturities

Leases - Summary of Maturities of Lessee Operating Lease (Details) $ in Thousands	Sep. 30, 2019USD ($)
Leases [Abstract]
2019 (excluding the nine-months ended September 30, 2019)	$ 84
2020	340
2021	347
2022	331
2023	214
Thereafter	6
Total lease payments	1,322
Less imputed interest	(149)
Total	$ 1,173

Per Share Amounts (Details Text

Per Share Amounts (Details Textual) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Amount of antidilutive securities excluded from computation (in shares)	513	176	513	519

Per Share Amounts - Schedule of

Per Share Amounts - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net income attributable to American Shared Hospital Services	$ 165	$ 168	$ 466	$ 845
Weighted average common shares for basic earnings per share (in shares)	5,889	5,841	5,899	5,831
Diluted effect of stock options and restricted stock (in shares)	19	50	18	24
Weighted average common shares for diluted earnings per share (in shares)	5,908	5,891	5,917	5,855
Basic earnings per share (in USD per share)	$ 0.03	$ 0.03	$ 0.08	$ 0.14
Diluted earnings per share (in USD per share)	$ 0.03	$ 0.03	$ 0.08	$ 0.14

Stock-based Compensation (Detai

Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	Jan. 04, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017	Jun. 30, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense		$ 62	$ 57	$ 170	$ 169	$ 108
Nonvested awards, unrecognized stock-based compensation expense		434		$ 434
Expected term for cost to be recognized (in years)				5 years
Incentive Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)							1,630,000
Nonvested awards, unrecognized stock-based compensation expense		$ 94		$ 94
Performance Share Award Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards (in shares)	161,766
Unvested awards (in shares)		129,000		129,000

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019	Jan. 01, 2018
Stock Options
Stock Options, Outstanding Beginning Balance (in shares)	603	613			613	615
Stock Options, Granted (in shares)	18	16
Stock Options, Exercised (in shares)	(16)
Stock Options, Forfeited (in shares)	(12)	(18)
Stock Options, Outstanding Ending Balance (in shares)	603	613			613	615
Stock Options, Exercisable (in shares)	478	389
Grant Date Weighted- Average Exercise Price
Grant Date Weighted-Average Exercise Price, Beginning balance (in USD per share)	$ 2.86	$ 2.85			$ 2.85	$ 2.87
Grant Date Weighted Average Exercise Price, Granted (in USD per share)	2.91	2.68
Grant Date Weighted Average Exercise Price, Exercised (in USD per share)	2.59
Grant Date Weighted Average Exercise Price, Forfeited (in USD per share)	3.05	3.15
Grant Date Weighted-Average Exercise Price, Ending balance (in USD per share)	2.86	2.85			$ 2.85	$ 2.87
Grant Date Weighted Average Exercise Price, Exercisable (in USD per share)	$ 2.86	$ 2.86
Weighted- Average Remaining Contractual Life (in Years)
Weighted Average Remaining Contractual Life (Years), Beginning Balance	2 years 1 month 2 days	2 years 11 months 4 days	3 years 2 months 4 days	3 years 5 months 23 days
Weighted Average Remaining Contractual Life (Years), Granted	7 years	6 years 11 months 15 days
Weighted Average Remaining Contractual Life (Years), Ending Balance	2 years 1 month 2 days	2 years 11 months 4 days	3 years 2 months 4 days	3 years 5 months 23 days
Weighted Average Remaining Contractual Life (Years), Exercisable	1 year 11 months 19 days	2 years 9 months 29 days
Intrinsic Value
Intrinsic Value, Outstanding Beginning Balance	$ 42	$ 337			$ 0	$ 0
Intrinsic Value, Grants in Period	0	0
Intrinsic Value, Exercises in Period	0
Intrinsic Value, Forfeitures in Period	0	0
Intrinsic Value, Outstanding Ending Balance	42	337			$ 0	$ 0
Intrinsic Value, Exercisable End of Period	$ 0	$ 0